Reimbursement Strategy

Even if you think your device gets the patient out of high-cost care settings and offers a net cost savings, and thus justifies a higher price than the gold standard, the clinical evidence used to get through the FDA is often insufficient to sell to the Centers for Medicare & Medicaid Services.

Validated clinical evidence and outcomes are the most important thing to offer payers, and the body of data used to obtain FDA’s approval or clearance will not suffice most of the time. Avoiding a surprise reimbursement story, includes determining the value proposition of your customer, which includes both the insurer and the provider, both today and in times to come. FDA and CMS have different missions – CMS focuses on whether the product is reasonable and necessary while the FDA focuses on whether the product is safe and efficacious. One of the big questions CMS has to ask is whether outcomes are better with the new offering and whether the technology is otherwise an improvement over what is already available. CMS is unwilling to pay for expensive medical devices that seem to offer no advantages over the current state of the art.

One of the challenges for device makers trying to do business in the U.S. is that reimbursement is decentralized and involves a surprising number of payers in addition to the uncertainties tied to healthcare reform. Only about 10%-15% of all Medicare coverage decisions are reviewed by CMS, with the balance handled by local Medicare carriers.

It is critical for you to have documentation that a code is ready for the device and the associated procedure because doctors and hospital administrators will not buy your product without that code. Learn more about the reimbursement process by watching this video.

Conduct your reimbursement analysis using information gathered on the final solution concept under development and/or proxy devices. Be sure to understand the mechanics related codes (existing versus new); coverage decisions (Medicare, large commercial payers, and payers outside the U.S.); reimbursement levels; and the status of technology assessment in the given field. Identify critical gaps in codes, coverage, and reimbursement payments that should be addressed via a reimbursement strategy. Rank payers and technology assessment groups based on expected perception of your technology.

CTIP’s steering committee and advisory board include reimbursement experts that can help you develop a reimbursement strategy. CTIP can also host educational seminars and workshops on this topic. For more information, contact us at info@scctip.com or call 323.361.8368.

Reimbursement Resources